Conference Coverage – WCLC 2025 Highlights
Expert insights and discussions from WCLC 2025 on the latest research developments, therapeutic advancements, and their application in lung cancer clinical decision-making.
Faculty Chair
Corey J. Langer, MD, FACP
University of Pennsylvania, Philadelphia, USA
FACULTY MEMBERS
Federico Cappuzzo, MD, PhD
Regina Elena National Cancer Institute, Rome, Italy
Luis Paz-Ares, MD, PhD
Hospital Universitario 12 de Octubre, Madrid, Spain
Natasha B. Leighl, MD, FRCPC, FASCO
Princess Margaret Cancer Centre, Toronto, ON, Canada
Hossein Borghaei, DO
Fox Chase Cancer Center, Philadelphia, PA, USA
Marina Chiara Garassino, MD
University of Chicago, Chicago, IL, USA
Helen Ross, MD
Rush Cancer Center, Chicago, IL, USA
Ignacio Wistuba, MD
Moffitt Cancer Center, Tampa, FL, USA
Sandip Patel, MD
University of California, San Diego, CA, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- EGFR Inhibition in Advanced NSCLC: Multiple Options Emerge
- Oncogenic Drivers and Other Mutations in Advanced NSCLC
- Targeted Therapy in Resectable NSCLC
- Immunotherapy in Resectable NSCLC
- Immunotherapy in Stage III/IV NSCLC
- New Agents and Approaches in SCLC
